Sanofi-Aventis, one of the world’s largest drugmakers, has approached big shareholders of Belgium’s Solvay about buying its pharmaceuticals division, thought to be worth €5bn ($6.6bn).

Sanofi last month approached Solvac, the ­family-owned holding vehicle that controls 30 per cent of Solvay, according to ­people familiar with the situation.